Cerenome, Inc.
Formerly Plus Therapeutics, Inc.
Cerenome, Inc. is listed today as Cerenome, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2026 | $3 M | Private placement after listing | $2 to $10 million | equity, debt, options | SEC | |
| May 2009 | $4 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cerenome, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).
SEC Form D · Sep 2026
The industry group it chose in its notices: Other Health Care.
SEC Form D · Sep 2026
That is all the official record says: Cerenome, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cerenome, Inc. are on record.
Investors#
No investor of Cerenome, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 41 investors.
Largest shareholders today
Institutions holding Cerenome, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$1 M4.02%
- BlackRock, Inc.$0 M1.31%
- Geode Capital Management, LLC$0 M1.08%
- Vanguard Fiduciary Trust Co$0 M0.49%
- Ashton Thomas Private Wealth, LLC$0 M0.45%
- State Street Corp$0 M0.41%
- Northern Trust Corp$0 M0.19%
- XTX Topco Ltd$0 M0.15%
- UBS Group AG$0 M0.04%
- Nuveen, LLC$0 M0.03%
- Vanguard Global Advisers, LLC$0 M0.03%
- Osaic Holdings, Inc.$0 M0.03%
- Tower Research Capital LLC (TRC)$0 M0.02%
- Jpmorgan Chase & Co$0 M0.01%
- Royal Bank Of Canada$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew H. Sims | Chief Financial Officer | Sep 2026 |
| Marc H. Hedrick | President and Chief Executive Officer | Sep 2026 |
| Christopher J Calhoun | Executive officer | Jun 2009 |
| Marc H Hedrick | Executive officer | Jun 2009 |
| Mark E Saad | Executive officer | Jun 2009 |
| An H. van Es-Johansson | Director | Sep 2026 |
| Howard H. Clowes | Director | Sep 2026 |
| Kyle A. Guse | Director | Sep 2026 |
| Marc H. Hedrick | President and Chief Executive Officer | Sep 2026 |
| Richard J. Hawkins | Chairman of the Board | Sep 2026 |
| Ronald A. Andrews | Director | Sep 2026 |
| Christopher J Calhoun | Director | Jun 2009 |
| David M Rickey | Director | Jun 2009 |
| E Carmack Holmes, MD | Director | Jun 2009 |
| Marc H Hedrick | Director | Jun 2009 |
| Paul W Hawran | Director | Jun 2009 |
| Richard J Hawkins | Director | Jun 2009 |
| Ronald D Henriksen | Director | Jun 2009 |
About
Biopharmaceutical company.
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.